Asparlas (Calaspargase pegol-mknl)

Asparlas is an asparagine specific enzyme used as a component of a multi-agent chemotherapeutic regimen to treat acute lymphoblastic leukemia (ALL) in pediatric and young adult patients aged 1 month to 21 years.

Recommended Dosage: The recommended dose of asparlas injection is 2,500 units/m2 given intravenously no more frequently than every 3 weeks (21 days). 

Premedicate patients with acetaminophen, an H-1 receptor blocker (such as diphenhydramine), and an H-2 receptor blocker (such as famotidine) 30 to 60 minutes before the administration of Calaspargase pegol-mknl to reduce the risk as well as severity of both infusion and hypersensitivity reactions. 

• Grade 3/4 hypersensitivity reactions including anaphylaxis may occur with Calaspargase injection. Hypersensitivity reactions observed with other asparaginases include lip swelling, eye swelling, angioedema, blood pressure decreased, bronchospasm, erythema, dyspnea, pruritus and rash. 
• Cases of pancreatitis may occur with injection Asparlas. Inform patients of the signs/symptoms of pancreatitis, which, if left untreated, could be fatal. Assess serum amylase or lipase levels to identify early signs of pancreatic inflammation. Discontinue therapy if pancreatitis is suspected; if pancreatitis is confirmed, do not resume therapy. 
• Serious thrombotic events, including sagittal sinus thrombosis, may be reported with Calaspargase pegol-mknl treatment. Discontinue therapy in those experiencing serious thrombotic events. 
• Hemorrhage associated with increased partial thromboplastin time (PTT), increased prothrombin time (PT), and hypofibrinogenemia may be reported in patients receiving Asparlas 3,750 units/5 mL. Assess patients with signs/symptoms of hemorrhage with coagulation parameters including PTT, PT, fibrinogen.
• Abnormal liver function and hepatotoxicity, including reduced serum albumin, elevations of transaminase, bilirubin (direct/indirect), and plasma fibrinogen can occur. Assess bilirubin and transaminases weekly, during cycles of treatment that include Calaspargase through 6 weeks after the final dose of Calaspargase pegol-mknl. 
• Calaspargase pegol-mknl can cause fetal harm if used by a pregnant woman. Pregnancy testing is required in females of reproductive age prior to initiating therapy. Due to the potential for side effects in the breastfed child, women should not breastfeed throughout the treatment and for 3 months after the final dose.

Indian Pharma Network is able to source the ASPARLAS (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma Network offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Asparlas®?

Calaspargase pegol-mknl is Generic Name for the trade name drug Asparlas®.

What is the Manufacturer Name of Asparlas®?

Asparlas® is manufactured by Servier Pharmaceuticals LLC. 

Is Asparlas® approved by the FDA?

Yes, Asparlas® is approved by the FDA. Date of initial approval: December 20, 2018.

What is the dosage and form of Asparlas® supplied?

Asparlas® is supplied as Injection: 3,750 units/5 mL (750 units/mL) clear, colorless solution in a single-dose vial for intravenous use. 

What are the most common side effects with Asparlas®? 

The most common side effects with Asparlas® include: bilirubin increased, elevated transaminase, pancreatitis and abnormal clotting studies.

How much does Asparlas® cost in India?

Asparlas injection cost in India is reasonable. In order to procure this ALL medication authentically, you can Call/WhatsApp +91-9310090915, or dial TOLL-FREE: 1800-889-1064, or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Asparlas®?

Store Asparlas refrigerated at 2-8°C (36-46°F) in the original carton to protect from light. Neither shake nor freeze product. Unopened vials may be stored at room temperature 15-25°C (59-77°F) for no more than 48 hours.

Where can I get Asparlas® at the best price in India?

To get the best Asparlas price in India, you can connect with  Indian Pharma Network (IPN), or any other authorized Pharmaceutical Wholesaler Company which is certified by WHO-GDP and ISO 9001:2008. A medical prescription is needed while buying Asparlas (Calaspargase pegol-mknl).

Is it safe to buy Asparlas® online from India? 

Yes, You can buy Asparlas injection online from India authentically from https://www.indianpharmanetwork.in/ if Asparlas® is not available or has not been approved in your home country.

What are the Highlights of prescribing information for Asparlas®?

Click Here to download full  Asparlas prescribing information.